MCID: ALD013
MIFTS: 36

Aldosterone-Producing Adenoma

Aliases & Classifications for Aldosterone-Producing Adenoma

MalaCards integrated aliases for Aldosterone-Producing Adenoma:

Name: Aldosterone-Producing Adenoma 43 17
Conn Adenoma 43 70
Primary Aldosteronism Due to Conn Adenoma 43
Aldosterone-Secreting Adenoma 43
Aldosteronoma 43

External Ids:

UMLS 70 C0009777

Summaries for Aldosterone-Producing Adenoma

MedlinePlus Genetics : 43 An aldosterone-producing adenoma is a noncancerous (benign) tumor that develops in an adrenal gland, which is a small hormone-producing gland located on top of each kidney. In most cases, individuals develop a single tumor in one of the adrenal glands. The adrenal tumor produces too much of the hormone aldosterone, which is a condition known as primary hyperaldosteronism. Aldosterone helps regulate the body's fluid levels and blood pressure by controlling the amount of salt retained by the kidneys. Excess aldosterone causes the kidneys to retain more salt than normal, which increases the body's fluid levels and blood pressure. People with an aldosterone-producing adenoma may develop severe high blood pressure (hypertension), and they have an increased risk of heart attack, stroke, or an irregular heart beat (atrial fibrillation).

MalaCards based summary : Aldosterone-Producing Adenoma, also known as conn adenoma, is related to adenoma and hypokalemia. An important gene associated with Aldosterone-Producing Adenoma is KCNJ5 (Potassium Inwardly Rectifying Channel Subfamily J Member 5), and among its related pathways/superpathways are cGMP-PKG signaling pathway and Oxytocin signaling pathway. The drugs Hydrocortisone and Hydrocortisone acetate have been mentioned in the context of this disorder. Affiliated tissues include heart, adrenal gland and cortex, and related phenotype is cardiovascular system.

Wikipedia : 73 Primary aldosteronism (PA), also known as primary hyperaldosteronism or Conn's syndrome, refers to the... more...

Related Diseases for Aldosterone-Producing Adenoma

Diseases related to Aldosterone-Producing Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 106)
# Related Disease Score Top Affiliating Genes
1 adenoma 31.1 KCNJ5 CYP21A2 CYP11B2
2 hypokalemia 31.1 KCNJ5 CACNA1D
3 conn's syndrome 30.7 KCNJ5 CYP21A2 CYP11B2 CACNA1D AGTR1
4 adrenal adenoma 30.6 KCNJ5 CYP21A2 CYP11B2
5 adrenal cortical carcinoma 30.0 CYP21A2 CYP11B2
6 46,xy sex reversal 2 30.0 CYP21A2 CYP11B2
7 hyperaldosteronism, familial, type i 29.8 KCNJ5 CYP11B2 CACNA1D
8 familial hyperaldosteronism 29.8 KCNJ5 CYP11B2 AGTR1
9 hypertension, essential 29.6 KCNJ5 CYP11B2 CACNA1D AGTR2 AGTR1
10 adrenal carcinoma 29.4 KCNJ5 CYP21A2 CYP11B2
11 dilated cardiomyopathy 28.8 KCNJ5 CYP11B2 CACNA1D AGTR1
12 hyperaldosteronism, familial, type ii 11.2
13 adrenal cortical adenoma 10.5
14 pheochromocytoma 10.4
15 adrenal gland pheochromocytoma 10.4
16 adrenocortical carcinoma, hereditary 10.2
17 malignant hypertension 10.2
18 adrenal cortical adenocarcinoma 10.2
19 acth-independent macronodular adrenal hyperplasia 10.2
20 proteinuria, chronic benign 10.2
21 glucose intolerance 10.2
22 hyperparathyroidism 10.2
23 47,xyy 10.2
24 hypoaldosteronism 10.2
25 periodic paralysis 10.2
26 pure autonomic failure 10.0
27 type 2 diabetes mellitus 10.0
28 fibrosis of extraocular muscles, congenital, 1 10.0
29 hypokalemic periodic paralysis, type 1 10.0
30 liddle syndrome 1 10.0
31 retinoblastoma 10.0
32 apparent mineralocorticoid excess 10.0
33 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.0
34 body mass index quantitative trait locus 1 10.0
35 metabolic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration 10.0
36 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 10.0
37 familial adenomatous polyposis 10.0
38 sleep apnea 10.0
39 pre-eclampsia 10.0
40 portal hypertension 10.0
41 primary hyperparathyroidism 10.0
42 hepatic coma 10.0
43 hepatic encephalopathy 10.0
44 renovascular hypertension 10.0
45 pneumothorax 10.0
46 glomerulonephritis 10.0
47 anuria 10.0
48 myopathy 10.0
49 proliferative glomerulonephritis 10.0
50 mesangial proliferative glomerulonephritis 10.0

Graphical network of the top 20 diseases related to Aldosterone-Producing Adenoma:



Diseases related to Aldosterone-Producing Adenoma

Symptoms & Phenotypes for Aldosterone-Producing Adenoma

MGI Mouse Phenotypes related to Aldosterone-Producing Adenoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.02 AGTR1 AGTR2 CACNA1D CYP11B2 KCNJ5

Drugs & Therapeutics for Aldosterone-Producing Adenoma

Drugs for Aldosterone-Producing Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 51)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
2
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
3 Kava Approved, Investigational, Nutraceutical Phase 3 9000-38-8
4 Adrenergic alpha-Agonists Phase 3
5 Respiratory System Agents Phase 3
6 Adrenergic Agonists Phase 3
7 Anti-Asthmatic Agents Phase 3
8 Melanocyte-Stimulating Hormones Phase 3
9 Adrenergic beta-Agonists Phase 3
10 Adrenocorticotropic Hormone Phase 3
11 Mydriatics Phase 3
12 Adrenergic Agents Phase 3
13 Hydrocortisone hemisuccinate Phase 3
14 Hydrocortisone 17-butyrate 21-propionate Phase 3
15 Neurotransmitter Agents Phase 3
16 beta-Endorphin Phase 3
17 Sympathomimetics Phase 3
18 Vasoconstrictor Agents Phase 3
19 Bronchodilator Agents Phase 3
20
Roxithromycin Approved, Investigational, Withdrawn 80214-83-1 444037 6915744
21
Clarithromycin Approved 81103-11-9 84029
22
Dopamine Approved 51-61-6, 62-31-7 681
23
Olmesartan Approved, Investigational 144689-24-7, 144689-63-4 158781 130881
24
Angiotensin II Approved, Investigational 68521-88-0, 4474-91-3, 11128-99-7 172198
25
Eplerenone Approved 107724-20-9 150310 443872
26
Spironolactone Approved 1952-01-7, 52-01-7 5833
27
Epinephrine Approved, Vet_approved 51-43-4 5816
28
Racepinephrine Approved 329-65-7 838
29
Canrenone Investigational 976-71-6 13789
30 Anti-Inflammatory Agents
31 Hydrocortisone-17-butyrate
32 Cytochrome P-450 CYP3A Inhibitors
33 Anti-Bacterial Agents
34 Anti-Infective Agents
35 Cytochrome P-450 Enzyme Inhibitors
36 Adrenergic beta-Antagonists
37 Angiotensin II Type 1 Receptor Blockers
38
Olmesartan medoxomil 144689-63-4 130881
39 Angiotensin Receptor Antagonists
40 Angiotensin-Converting Enzyme Inhibitors
41 Giapreza
42 Angiotensinogen
43 Antihypertensive Agents
44 Metomidate
45 Hormones
46 Epinephryl borate
47 Mineralocorticoid Receptor Antagonists
48 Mineralocorticoids
49 Hormone Antagonists
50 Diuretics, Potassium Sparing

Interventional clinical trials:

(show all 13)
# Name Status NCT ID Phase Drugs
1 Towards Cost-effective Management of Patients With Hypertension Due to Primary Aldosteronism: Adrenal Vein Sampling or Ct-scan? Completed NCT01096654 Phase 3
2 The Intra-Procedural Cortisol Assay During Adrenal Vein Sampling: Rationale andDesign of A Randomized Study (I-PADUA) Unknown status NCT03449797
3 Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA): A Study Of Personalized Diagnosis of Primary Aldosteronism With Implications For Treatment Unknown status NCT03414918 Clarithromycin
4 Laparoscopic Adrenalectomy Versus Radiofrequency Ablation for Aldosterone-producing Adenoma: a Prospective Randomized Controlled Trial Unknown status NCT02030587
5 Expression of D2-Like Dopamine Receptor of Human Aldosterone-Producing Adenoma and Its Role in Regulation of Aldosterone Secretion and Cell Proliferation Unknown status NCT00173446
6 Effects of Mineralocorticoid and AT-1 Receptor Antagonism on the Aldosterone-Renin Ratio (ARR) In Primary Aldosteronism Patients (EMIRA Study): Rationale and Design Completed NCT04185857 canrenone 50-100 mg orally once a day;olmesartan 10-20 mg orally once a day
7 Efficacy and Safety of Renal Sympathetic Denervation From The Adventitia on Hypertension in Patients With Primary Aldosteronism Completed NCT02642445
8 Characteristics Predicting Clinically Relevant Reduction of Hypertension Following Adrenalectomy for Primary Aldosteronism: a Multicenter Analysis Completed NCT04761354
9 Glucose Metabolism in Subjects With Aldosterone-Producing Adenomas Completed NCT02362308 mineralocorticoid receptor antagonist
10 Changes in Tissue Potassium Amount Before and After Treatment of Primary Hyperaldosteronism Assessed by 39K-MRI Recruiting NCT04251780 Drug treatment of Hyperaldosteronism
11 Feasibility Study of RadioFrequency Endoscopic ABlation, With ULtrasound Guidance, as a Non-surgical, Adrenal Sparing Treatment for Aldosterone-producing Adenomas Recruiting NCT03405025
12 IS Metomidate PET-CT Superior to Adrenal Venous Sampling in Predicting Outcome From Adrenalectomy in Patients With Primary Hyperaldosteronism Recruiting NCT02945904
13 Investigating Salt Taste Threshold in Patients Being Investigated for Primary Hyperaldosteronism Before and After Treatment. Not yet recruiting NCT04556279 Aldosterone Antagonist

Search NIH Clinical Center for Aldosterone-Producing Adenoma

Genetic Tests for Aldosterone-Producing Adenoma

Anatomical Context for Aldosterone-Producing Adenoma

MalaCards organs/tissues related to Aldosterone-Producing Adenoma:

40
Heart, Adrenal Gland, Cortex, Adrenal Cortex, Endothelial, Kidney, Smooth Muscle

Publications for Aldosterone-Producing Adenoma

Articles related to Aldosterone-Producing Adenoma:

(show top 50) (show all 935)
# Title Authors PMID Year
1
Aldosterone-producing adenoma associated with non-suppressed renin: a case series. 61
33785905 2021
2
Computed tomography combined with confirmatory tests for the diagnosis of aldosterone-producing adenoma. 61
33100281 2021
3
Aldosterone and cortisol synthesis regulation by angiotensin-(1-7) and angiotensin-converting enzyme 2 in the human adrenal cortex. 61
33657582 2021
4
Superselective adrenal arterial embolization for idiopathic hyperaldosteronism: 12-month results from a proof-of-principle trial. 61
33605538 2021
5
Association of Adrenal Venous Sampling With Outcomes in Primary Aldosteronism for Unilateral Adenomas. 61
33146695 2021
6
Letter to the editor on "Ablation versus laparoscopic adrenalectomy for the treatment of aldosterone-producing adenoma: a meta-analysis". 61
33624132 2021
7
Thirty-six-month results of laparoscopic-based renal denervation plus unilateral laparoscopic adrenalectomy for the treatment of patients with resistant hypertension caused by unilateral aldosterone-producing adenoma. 61
33591620 2021
8
Comparison of biomarkers of endothelial dysfunction and microvascular endothelial function in patients with primary aldosteronism and essential hypertension. 61
33678006 2021
9
Diurnal blood pressure pattern and cardiac damage in hypertensive patients with primary aldosteronism. 61
33474712 2021
10
KCNJ5 Mutation Contributes to Complete Clinical Success in Aldosterone-Producing Adenoma: A Study From a Single Center. 61
33678553 2021
11
KCNJ5 Somatic Mutations in Aldosterone-Producing Adenoma Are Associated With a Worse Baseline Status and Better Recovery of Left Ventricular Remodeling and Diastolic Function. 61
33249859 2021
12
Ablation versus laparoscopic adrenalectomy for the treatment of aldosterone‑producing adenoma: a meta-analysis. 61
33386911 2021
13
Feasibility of Iodine-131 6β-Methyl-Iodo-19 Norcholesterol (NP-59) Scintigraphy to Complement Adrenal Venous Sampling in Management of Primary Aldosteronism: A Case Series. 61
33688238 2021
14
Significance of aldosterone gradient within left adrenal vein in diagnosing unilateral subtype of primary aldosteronism. 61
32854164 2021
15
Diverse pathological lesions of primary aldosteronism and their clinical significance. 61
33437027 2021
16
Aldosterone is Aberrantly Regulated by Various Stimuli in a High Proportion of Patients with Primary Aldosteronism. 61
33000146 2021
17
Cortisol Co-Secretion and Clinical Usefulness of ACTH Stimulation Test in Primary Aldosteronism: A Systematic Review and Biases in Epidemiological Studies. 61
33796078 2021
18
Aldosterone-induced cardiac damage in primary aldosteronism depends on its subtypes. 61
33268573 2021
19
Update: Selective adrenal venous sampling (AVS) - Indication, technique, and significance. 61
33327032 2020
20
131I-6β-iodomethyl-19-norcholesterol adrenal scintigraphy as an alternative to adrenal venous sampling in differentiating aldosterone-producing adenoma from bilateral idiopathic hyperaldosteronism. 61
32956247 2020
21
A Comparison of Adrenalectomy and Eplerenone on Vascular Function in Patients with Aldosterone-producing Adenoma. 61
32818224 2020
22
Different pathogenesis of glucose intolerance in two subtypes of primary aldosteronism: Aldosterone-producing adenoma and idiopathic hyperaldosteronism. 61
32470155 2020
23
Prevalence of Somatic Mutations in Aldosterone-Producing Adenomas in Japanese Patients. 61
32844168 2020
24
Presence of Subclinical Hypercortisolism in Clinical Aldosterone-Producing Adenomas Predicts Lower Clinical Success. 61
32921192 2020
25
Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism. 61
32206838 2020
26
The landscape of molecular mechanism for aldosterone production in aldosterone-producing adenoma. 61
32968034 2020
27
Clinical outcomes of laparoscopic-based renal denervation plus adrenalectomy vs adrenalectomy alone for treating resistant hypertension caused by unilateral aldosterone-producing adenoma. 61
32812324 2020
28
Prevalence of primary aldosteronism and association with cardiovascular complications in patients with resistant and refractory hypertension. 61
32384388 2020
29
Precise Mapping of Intra-Adrenal Aldosterone Activities Provides a Novel Surgical Strategy for Primary Aldosteronism. 61
32536272 2020
30
Genetic and Genomic Mechanisms of Primary Aldosteronism. 61
32563556 2020
31
Primary Hyperaldosteronism in End-Stage Renal Disease: Diagnostic Challenges and Treatment Considerations. 61
32923203 2020
32
Exploration Of The Seated Saline Suppression Test For The Diagnosis Of Primary Aldosteronism In The Chinese Population. 61
33471680 2020
33
Association of visceral adiposity and clinical outcome among patients with aldosterone producing adenoma. 61
32713841 2020
34
Angiotensin II Type 1 Receptor Autoantibodies in Primary Aldosteronism. 61
32168525 2020
35
Age, Gender, and Body Mass Index as Determinants of Surgical Outcome in Primary Aldosteronism. 61
32252109 2020
36
The risk factors for hepatic steatosis in patients with primary aldosteronism. 61
32213734 2020
37
Primary antiphospholipid syndrome, Addison disease, and adrenal incidentaloma. 61
32146613 2020
38
Hypokalemia and the Prevalence of Primary Aldosteronism. 61
32252108 2020
39
Insulin secretion and sensitivity before and after surgical treatment for aldosterone-producing adenoma. 61
31676325 2020
40
Appropriate timing for a biochemical evaluation after adrenalectomy for unilateral aldosterone-producing adenoma. 61
32068902 2020
41
Long-Term Results of Laparoscopic Partial Versus Total Adrenalectomy for Aldosterone Producing Adenoma. 61
32309875 2020
42
Primary aldosteronism in a general population sample. The Czech post-MONICA study. 61
32036692 2020
43
Role of Mast Cells in the Control of Aldosterone Secretion. 61
32215882 2020
44
MicroRNAs and Adrenocortical Tumors: Where do we Stand on Primary Aldosteronism? 61
32168526 2020
45
Immunohistochemistry of the Human Adrenal CYP11B2 in Normal Individuals and in Patients with Primary Aldosteronism. 61
32289837 2020
46
Developments in Primary Aldosteronism Subtyping Using Steroid Profiling. 61
32330948 2020
47
Impact of immunohistochemistry on the diagnosis and management of primary aldosteronism: An important tool for improved patient follow-up. 61
30654730 2020
48
[Clinical Characteristics of Aldosterone Producing Adenoma and Idiopathic Hyperaldosteronism with Obstructive Sleep Apnea Hypopnea Syndrome]. 61
32543133 2020
49
[The Value of Serum Potassium and Ratio of Sodium to Potassium after Saline Infusion Test in Differential Diagnosis of Primary Hyperaldosteronism]. 61
32543131 2020
50
Lipoprotein insulin resistance score and branched-chain amino acids increase after adrenalectomy for unilateral aldosterone-producing adenoma: a preliminary study. 61
32133607 2020

Variations for Aldosterone-Producing Adenoma

Expression for Aldosterone-Producing Adenoma

Search GEO for disease gene expression data for Aldosterone-Producing Adenoma.

Pathways for Aldosterone-Producing Adenoma

Pathways related to Aldosterone-Producing Adenoma according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12 CACNA1D AGTR2 AGTR1
2
Show member pathways
11.89 KCNJ5 CACNA1D AGTR1
3
Show member pathways
11.79 KCNJ5 CYP21A2 CYP11B2 CACNA1D AGTR1
4 11.56 KCNJ5 CACNA1D
5
Show member pathways
11.38 CYP21A2 CYP11B2
6 11.3 CACNA1D AGTR1
7
Show member pathways
11.26 CYP21A2 CYP11B2
8 11.21 KCNJ5 CACNA1D
9 11.12 KCNJ5 CACNA1D
10
Show member pathways
11.03 CYP11B2 AGTR2 AGTR1
11
Show member pathways
10.48 CYP21A2 CYP11B2

GO Terms for Aldosterone-Producing Adenoma

Biological processes related to Aldosterone-Producing Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 steroid metabolic process GO:0008202 9.46 CYP21A2 CYP11B2
2 steroid biosynthetic process GO:0006694 9.43 CYP21A2 CYP11B2
3 regulation of heart rate by cardiac conduction GO:0086091 9.4 KCNJ5 CACNA1D
4 sterol metabolic process GO:0016125 9.37 CYP21A2 CYP11B2
5 regulation of blood vessel diameter GO:0097746 9.32 AGTR2 AGTR1
6 angiotensin-activated signaling pathway GO:0038166 9.26 AGTR2 AGTR1
7 glucocorticoid biosynthetic process GO:0006704 9.16 CYP21A2 CYP11B2
8 mineralocorticoid biosynthetic process GO:0006705 8.96 CYP21A2 CYP11B2
9 renin-angiotensin regulation of aldosterone production GO:0002018 8.62 AGTR2 AGTR1

Molecular functions related to Aldosterone-Producing Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 monooxygenase activity GO:0004497 9.26 CYP21A2 CYP11B2
2 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.16 CYP21A2 CYP11B2
3 steroid hydroxylase activity GO:0008395 8.96 CYP21A2 CYP11B2
4 angiotensin type II receptor activity GO:0004945 8.62 AGTR2 AGTR1

Sources for Aldosterone-Producing Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....